Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 680,001 shares, a growth of 161.3% from the March 15th total of 260,259 shares. Approximately 104.8% of the company’s stock are short sold. Based on an average daily trading volume, of 5,931,820 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned 0.84% of Onconetix as of its most recent SEC filing. 23.89% of the stock is currently owned by institutional investors.

Onconetix Stock Down 26.6%

Shares of NASDAQ:ONCO opened at $0.80 on Tuesday. The firm has a fifty day moving average of $3.32 and a two-hundred day moving average of $9.14. The firm has a market capitalization of $524,800.00, a P/E ratio of 0.00 and a beta of 3.63. Onconetix has a 12-month low of $0.75 and a 12-month high of $74.29.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.